This study is testing a new medicine, CagriSema, for people with type 2 diabetes (a condition where the body struggles to control blood sugar). CagriSema will be compared to tirzepatide, a medicine some doctors already use. Participants will receive one of these treatments by chance, like flipping a coin. This study will last up to one and a half years. To join, participants must be at least 18 years old, have had type 2 diabetes for at least 180 days, and be stable on diabetes medication like metformin (a common diabetes drug) with or without another drug called an SGLT2 inhibitor (which helps kidneys remove sugar from the body) for at least 90 days. Pregnant women or those with certain health issues cannot join. If interested, discuss with your doctor.

• Study Duration: Up to 1.5 years
• Treatment: Random assignment to CagriSema or tirzepatide
• Eligibility: Must be stable on certain diabetes medications